Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immix Biopharma Reports Promising Initial Clinical Data for NXC-201 in Phase 1b/2 NEXICART-2 Trial for Relapsed/Refractory AL Amyloidosis Quiver Quantitative, Inc. - Thu Dec 19, 6:44PM CST

Four patients in the NEXICART-2 trial normalized disease markers after NXC-201 treatment, with promising initial responses reported.Quiver AI SummaryImmix Biopharma, Inc. announced positive initial clinical...

IMMX : 2.10 (-3.67%)
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis GlobeNewswire - Thu Dec 19, 8:35AM CST

IMMX : 2.10 (-3.67%)
Immix Biopharma Announces Promising Clinical Results for CAR-T Therapy NXC-201 in Treating Relapsed/Refractory AL Amyloidosis Quiver Quantitative, Inc. - Mon Dec 16, 7:00PM CST

NXC-201 shows promising efficacy and safety in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate.Quiver AI SummaryImmix Biopharma, Inc. announced promising results from the...

IMMX : 2.10 (-3.67%)
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis GlobeNewswire - Mon Dec 16, 8:48AM CST

IMMX : 2.10 (-3.67%)
Immix Biopharma Reports 75% Complete Response Rate and 31.5-Month Response Duration for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis at ASH 2024 Quiver Quantitative, Inc. - Tue Dec 10, 6:58PM CST

Immix Biopharma reports 75% complete response rate for CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients at ASH 2024.Quiver AI SummaryImmix Biopharma, Inc. reported promising results from its...

IMMX : 2.10 (-3.67%)
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 GlobeNewswire - Tue Dec 10, 8:39AM CST

IMMX : 2.10 (-3.67%)
Immix Biopharma to Host Conference Call on CAR-T NXC-201 Developments for AL Amyloidosis on December 10, 2024 Quiver Quantitative, Inc. - Mon Dec 9, 6:42PM CST

Immix Biopharma will discuss CAR-T NXC-201 developments in AL Amyloidosis on a December 10 conference call.Quiver AI SummaryImmix Biopharma, Inc. will hold a conference call on December 10, 2024, at 4:30...

IMMX : 2.10 (-3.67%)
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media GlobeNewswire - Mon Dec 9, 8:33AM CST

IMMX : 2.10 (-3.67%)
Immix Biopharma Reports 75% Response Rate in Relapsed/Refractory AL Amyloidosis Patients for NXC-201 Ahead of ASH Presentation Quiver Quantitative, Inc. - Mon Nov 25, 6:56PM CST

NXC-201 shows 75% response rate in relapsed/refractory AL Amyloidosis, with data presented at ASH meeting in December 2024.Quiver AI SummaryImmix Biopharma, Inc. announced promising clinical trial results...

IMMX : 2.10 (-3.67%)
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients GlobeNewswire - Mon Nov 25, 8:32AM CST

IMMX : 2.10 (-3.67%)

Barchart Exclusives

Bearish on the Market? 2 Defensive Stocks for Maximum Portfolio Protection. Barchart - 1 hour ago
As economic growth is anticipated to slow, UBS highlights these two dividend-paying defensive stocks as smart picks, shifting focus away from cyclical stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot